RxDoctor Payments DataLook up a doctor →

Kathleen Boone

Primary Care · Pawleys Island, SCNPI 1538143391

Payments from drug & device makers

$9,024in general payments, 2019–2025

Across 454 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$766
  • Amgen$566
  • Lilly USA, LLC$468
  • GSK$439
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$8,992100%
  • Education$320%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,024 in reported general payments places this provider in the 95th percentile of 115 primary care providers in South Carolina.

See all primary care providers in South Carolina

Medicare billing

Part B allowed, 2024
$27,164
Medicare patients
419
Services billed
1,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide144$199,489
EliquisApixaban106$108,113
MounjaroTirzepatide64$76,835
FarxigaDapagliflozin Propanediol42$52,917
TrulicityDulaglutide35$43,741
RybelsusSemaglutide17$37,698
JanuviaSitagliptin Phosphate28$34,206
XareltoRivaroxaban31$29,814
LinzessLinaclotide22$28,705
JardianceEmpagliflozin23$25,105
Wellbutrin XlBupropion Hcl11$21,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$19,968
MyrbetriqMirabegron15$13,831
Tresiba Flextouch U-200Insulin Degludec13$13,473
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$13,054

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,512$237,186161 claims
Lilly USA, LLCMounjaro, Trulicity$468$120,57699 claims
PfizerEliquis, Premarin$338$112,851120 claims
AstraZenecaFarxiga, Breztri Aerosphere$766$65,97153 claims
MerckJanuvia, Janumet, Janumet Xr$368$55,76756 claims
AbbVieLinzess, Synthroid$1,102$32,25889 claims
Johnson & JohnsonXarelto$82$29,81431 claims
Boehringer IngelheimJardiance$45$25,10523 claims
GSKTrelegy Ellipta$439$19,96820 claims
Astellas Pharma US IncMyrbetriq$43$13,83115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 115 primary care providers in South Carolina.

Other primary care in Pawleys Island

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →